Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Conventional cancer therapies often involve DNA damage or inhibition of oncogenic molecules without altering protein levels.
• Targeted Protein Degradation (TPD) is an emerging strategy that utilizes the cell's natural proteolysis machinery to eliminate specific proteins.

Purpose of the Study:

• To review the advancements in Targeted Protein Degradation (TPD) as a therapeutic strategy in cancer therapy.
• To highlight the different classes of TPD agents and their clinical translation.

Main Methods:

• Review of existing literature on Targeted Protein Degradation (TPD) agents.
• Focus on molecular glues, Proteolysis Targeting Chimeras (PROTACs), and Hydrophobic Tag (HyT)-based degraders.
• Analysis of clinical translation and key advances in the field.

Main Results:

• TPD offers advantages over conventional inhibitors, representing a paradigm shift in drug therapy.
• Approved anticancer agents like fulvestrant and thalidomide function via TPD.
• Systematic efforts have expanded the range of proteins targetable by TPD.

Conclusions:

• Molecular glues, PROTACs, and HyT-based degraders are key classes of TPD agents.
• Significant progress has been made in translating TPD strategies for clinical application in cancer.
• TPD is a promising therapeutic avenue for cancer treatment, offering new possibilities beyond traditional inhibition.